---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-046197"
form_type: "8-K"
ticker: "LXEO"
cik: "0001907108"
company_name: "Lexeo Therapeutics, Inc."
filed_at: "2024-04-22T23:59:59+00:00"
generated_at: "2026-06-03T14:32:10.123223+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lexeo Therapeutics licenses full data and IP for LX2006 FA cardiomyopathy gene therapy from Cornell

## Summary
- Upfront fees total $600,000; potential regulatory milestones up to $2.1M and commercial milestones up to $100M.
- Exclusive license to patent rights and non-exclusive know-how for AAVrh.10hFXN (LX2006), including right to reference IND.
- 11 participants dosed across two trials (Lexeo's SUNRISE-FA and Weill Cornell Phase 1A); no treatment-related SAEs reported.
- Interim clinical data readout expected mid-2024, combining data from both studies with up to 18-month follow-up.
- LX2006 has FDA Orphan Drug, Rare Pediatric Disease, and Fast Track designations for FA cardiomyopathy.

## SEC filing metadata
- accession: 0000950170-24-046197
- form_type: 8-K
- ticker: LXEO
- cik: 0001907108
- company_name: Lexeo Therapeutics, Inc.
- filed_at: 2024-04-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1907108/000095017024046197/0000950170-24-046197-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1907108/000095017024046197/lxeo-20240422.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-046197
- JSON: https://secwatch.observer/filing/0000950170-24-046197.json
- Plain text: https://secwatch.observer/filing/0000950170-24-046197.txt

## Key facts
- Material Agreements
  Lexeo Therapeutics, Inc. entered into Third License Agreement with Cornell University valued at $600,000 (effective 2024-04-21).
  - Action: entry
  - Agreement: license
  - Counterparty: Cornell University
  - Value: $600,000
  - Effective: 2024-04-21
  source text: On April 21, 2024, Lexeo Therapeutics, Inc. (the “Company”) entered into the Third License Agreement (the “License Agreement”) with Cornell University
  evidence_url: https://www.sec.gov/Archives/edgar/data/1907108/000095017024046197/0000950170-24-046197-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.